Clinical trials: Gastric/Esophageal Cancer
Locally Advanced Cancer, Metastatic Cancer
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
The purpose of this study is to determine if the radiotracer, [68Ga]Ga-ABY-025, used for PET imaging can help us better identify and visualize lesions or tumors, in patients who are receiving standard of care therapy HER2+…
- Conditions
- Locally Advanced Cancer, Metastatic Cancer, HER2, HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT06828588
- Testing
- [68Ga]Ga-ABY-025
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms
- Trial name
- NCT05208762
- Testing
- PF-08046054, pembrolizumab
- Where
- 62 sites in United States, Belgium and 9 more
- Volunteers
- 714 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Barrett Esophagus, Gastro Esophageal Reflux
Clinical Utility of WATS3D: A 5-Year Prospective Study
The purpose of this study is to create a registry (collect data and keep it in a research database) to learn more about two methods of taking small tissue samples from your esophagus (the esophagus is the tube that carries food…
- Conditions
- Barrett Esophagus, Gastro Esophageal Reflux, Esophageal Dysplasia, Esophageal Diseases
- Trial name
- NCT04312633
- Where
- United States
- Volunteers
- 90,000 people
- Sponsor
- CDx Diagnostics
Liver Cancer (Locally Advanced or Metastatic), Lung Cancer (NSCLC)
A Study of SH009 Injection in Patients With Advanced Solid Tumors.
Evaluate the efficacy and safety of SH009 injection therapy for patients with advanced solid tumors
- Conditions
- Liver Cancer (Locally Advanced or Metastatic), Lung Cancer (NSCLC), Head and Neck Cancer Squamous Cell Carcinoma, Breast Cancer (Locally Advanced or Metastatic)
- Trial name
- NCT07390838
- Testing
- SH009
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma
This phase II trial studies how well oxaliplatin, leucovorin calcium, and fluorouracil followed by surgery and response based concurrent chemotherapy and radiation therapy works in treating patients with cancer of the esophagus…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Gastric Cardia, Stage IIIA Esophageal Cancer
- Trial name
- NCT02037048
- Testing
- oxaliplatin, leucovorin calcium, fluorouracil
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Case Comprehensive Cancer Center
End of Life, Cancer
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
This cluster-randomized comparative effectiveness trial compares a technology-based supportive cancer care (SCC) approach with a redesigned team-based supportive cancer care (SCC) approach.
- Trial name
- NCT05297734
- Testing
- Receive technology-based supportive cancer care, Receive redesigned team-based supportive cancer care
- Where
- 17 sites in United States
- Volunteers
- 2,996 people
- Sponsor
- Stanford University
Esophageal Cancer, Gastric Cancer
Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00020787
- Testing
- G17DT Immunogen, cisplatin, fluorouracil
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Gastric Cancer
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
This study is a phase III, multi-centre study of olaparib in combination with paclitaxel, compared with placebo in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line…
- Trial name
- NCT01924533
- Testing
- Olaparib, Paclitaxel
- Where
- 57 sites in China, Japan and 2 more
- Volunteers
- 525 people
- Sponsor
- AstraZeneca
Melanoma, Non-small Cell Lung Cancer
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer
- Trial name
- NCT03329950
- Testing
- CDX-1140, CDX-301, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
Advanced Malignancies, Metastatic Cancer
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.
- Trial name
- NCT03126110
- Testing
- INCAGN01876, Nivolumab, Ipilimumab
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 145 people
- Sponsor
- Incyte Biosciences International Sàrl
Oesophageal Adenocarcinoma, Gastric Adenocarcinoma
Longitudinal Assessment of Biomarkers After Oesophagogastric Cancer Surgery
Oesophagogastric cancer (cancer of the gullet and stomach) is the fifth most common cancer in England and Wales with 16,000 new cases diagnosed every year. Survival rates are poor with only 15% surviving beyond 5 years.
- Trial name
- LABS (NCT06289374)
- Testing
- Biosample collection
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Imperial College London
Gastric Adenocarcinoma, Esophageal Adenocarcinoma
Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma
Gastric or gastroesophageal junction adenocarcinoma is commonly treated with chemotherapy before and after surgery. The chemotherapy regimen used in our institution, called DCF (docetaxel,cisplatic, 5-fluorouracil) is active…
- Trial name
- NCT01932580
- Testing
- FLOT (5-fluorouracil, oxaliplatin, docetaxel)
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- McGill University
Esophageal Neoplasms, Stomach Neoplasms
Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer
Improvements to treatment strategies for patients upper gastrointestinal cancers have produced an increasing population of people who remain free from disease recurrence in the long term.
- Conditions
- Esophageal Neoplasms, Stomach Neoplasms, Weight Loss, Malnutrition
- Trial name
- NCT02385617
- Testing
- Octreotide
- Where
- 2 sites in Ireland, Sweden
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- St. James's Hospital, Ireland
Gastrointestinal Cancer, Gastric Cancer
NOMAD-GI: Molecular-guided Non-operative Management and Organ Preservation Strategy After Precision Therapy in Gastrointestinal Cancers
The NOMAD-GI study is a single-center, bidirectional cohort study designed to evaluate the safety and efficacy of molecular biomarker-guided non-operative management (NOM) and organ preservation strategies after precision therapy…
- Conditions
- Gastrointestinal Cancer, Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Cancer
- Trial name
- NOMAD-GI (NCT07775859)
- Volunteers
- 200 people
- Sponsor
- Peking University Cancer Hospital & Institute
Esophagus Adenocarcinoma
Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery
The present clinical trial is a prospective, investigator-initiated, single-arm, open-label, multicenter phase II trial investigating whether a definite organ preservation therapy consisting of the combination of durvalumab with…
- Trial name
- NCT05713838
- Testing
- Durvalumab, FLOT, mFOLFOX-6
- Where
- 22 sites in Germany
- Volunteers
- 32 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Solid Tumor, EGFR Amplification
Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors
To evaluate the efficacy and safety of nimotuzumab in the treatment of EGFR-amplified advanced pan solid tumors (Lung/Esophageal/Gastric/Pancreatic /Colorectal / Head and neck Cervical).
- Trial name
- NCT06022276
- Testing
- Nimotuzumab
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Tianjin Medical University Second Hospital
Esophageal Carcinoma, Gastric Cancer (Diagnosis)
Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B)
This is a phase II open-label, basket clinical trial to assess the feasibility of systemic and Intraperitoneal chemotherapy in subjects with Gastrointestinal Malignancies with Peritoneal Carcinomatosis.
- Conditions
- Esophageal Carcinoma, Gastric Cancer (Diagnosis), Colorectal Adenocarcinoma, Appendiceal Adenocarcinoma
- Trial name
- NCT07795749
- Testing
- Paclitaxel Q2W, Paclitaxcel Q3W
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of California, Irvine
Esophageal Neoplasms, Gastric Neoplasm
Prevalence of Sub-epithelial Lesions Among Patients Undergoing EGDs in Egypt
Subepithelial lesions (SEL) are incidentally observed in the stomach of about 0.3% of middle-aged men and women; half of these are neoplastic.
- Conditions
- Esophageal Neoplasms, Gastric Neoplasm, Duodenal Neoplasms
- Trial name
- NCT04622098
- Testing
- Endoscopic ultrasound
- Where
- Egypt
- Volunteers
- 2,000 people
- Sponsor
- Kafrelsheikh University
Esophageal Cancer, Gastric Cancer
Prehabilitation in Patients With Esophageal or Gastric Cancers
Objectives: The primary objective of this study is to assess the feasibility of a internet-based preoperative exercise program in patients with esophageal or gastric cancers.
- Trial name
- NCT03418298
- Testing
- Prehabilitation group
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Gastric Cancer, Gastroesophageal Junction Cancer
Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer
The main purpose of this study is to compare how long patients with gastric or gastroesophageal junction cancer live after receiving nivolumab and ipilimumab or nivolumab and chemotherapy compared with patients receiving…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
- Trial name
- CheckMate649 (NCT02872116)
- Testing
- Nivolumab, Ipilimumab, Oxaliplatin
- Where
- 179 sites in United States, Argentina and 27 more
- Volunteers
- 2,031 people
- Sponsor
- Bristol-Myers Squibb